MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Gran Canaria Dr. Negrin (6)
2021
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2012
-
Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline acute lymphoblastic leukemia
Leukemia, Vol. 26, Núm. 11, pp. 2360-2366
2011
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2004
-
Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: Multiinstitutional laboratory trial
Clinical Chemistry, Vol. 50, Núm. 6, pp. 1088-1092
2001
-
Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation
British Journal of Haematology, Vol. 114, Núm. 4, pp. 931-936